These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19285001)

  • 1. Conformational detection of prion protein with biarsenical labeling and FlAsH fluorescence.
    Coleman BM; Nisbet RM; Han S; Cappai R; Hatters DM; Hill AF
    Biochem Biophys Res Commun; 2009 Mar; 380(3):564-8. PubMed ID: 19285001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing misfolding of the prion protein by trimethylamine N-oxide.
    Bennion BJ; DeMarco ML; Daggett V
    Biochemistry; 2004 Oct; 43(41):12955-63. PubMed ID: 15476389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copper induces increased beta-sheet content in the scrapie-susceptible ovine prion protein PrPVRQ compared with the resistant allelic variant PrPARR.
    Wong E; Thackray AM; Bujdoso R
    Biochem J; 2004 May; 380(Pt 1):273-82. PubMed ID: 14969585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The elusive intermediate on the folding pathway of the prion protein.
    Jenkins DC; Sylvester ID; Pinheiro TJ
    FEBS J; 2008 Mar; 275(6):1323-35. PubMed ID: 18279390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization.
    Kazlauskaite J; Sanghera N; Sylvester I; Vénien-Bryan C; Pinheiro TJ
    Biochemistry; 2003 Mar; 42(11):3295-304. PubMed ID: 12641461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assembly of natural and recombinant prion protein into fibrils.
    Leffers KW; Wille H; Stöhr J; Junger E; Prusiner SB; Riesner D
    Biol Chem; 2005 Jun; 386(6):569-80. PubMed ID: 16006244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular model of an alpha-helical prion protein dimer and its monomeric subunits as derived from chemical cross-linking and molecular modeling calculations.
    Kaimann T; Metzger S; Kuhlmann K; Brandt B; Birkmann E; Höltje HD; Riesner D
    J Mol Biol; 2008 Feb; 376(2):582-96. PubMed ID: 18158160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular bases of prion diseases].
    Rać M; Rać M
    Ann Acad Med Stetin; 2006; 52(3):5-13. PubMed ID: 17385343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetracysteine-tagged prion protein allows discrimination between the native and converted forms.
    Gaspersic J; Hafner-Bratkovic I; Stephan M; Veranic P; Bencina M; Vorberg I; Jerala R
    FEBS J; 2010 May; 277(9):2038-50. PubMed ID: 20345906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PrP N-terminal domain triggers PrP(Sc)-like aggregation of Dpl.
    Erlich P; Cesbron JY; Lemaire-Vieille C; Curt A; Andrieu JP; Schoehn G; Jamin M; Gagnon J
    Biochem Biophys Res Commun; 2008 Jan; 365(3):478-83. PubMed ID: 17997980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alkylating antitumor drug mechlorethamine conceals a structured PrP domain and inhibits in vitro prion amplification.
    Zhou X; Bi H; Wong J; Shimoji M; Wang Y; Yuan J; Xiao X; Wang GX; Zou WQ
    J Toxicol Environ Health A; 2011; 74(22-24):1493-503. PubMed ID: 22043910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural intermediates in the putative pathway from the cellular prion protein to the pathogenic form.
    Jansen K; Schäfer O; Birkmann E; Post K; Serban H; Prusiner SB; Riesner D
    Biol Chem; 2001 Apr; 382(4):683-91. PubMed ID: 11405232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of oligomeric prion-protein aggregates in a mouse model of prion disease.
    Sasaki K; Minaki H; Iwaki T
    J Pathol; 2009 Sep; 219(1):123-30. PubMed ID: 19479969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of PrP conformation using circular dichroism.
    Han S; Hill AF
    Methods Mol Biol; 2008; 459():145-59. PubMed ID: 18576154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring prion protein stability by NMR.
    Julien O; Graether SP; Sykes BD
    J Toxicol Environ Health A; 2009; 72(17-18):1069-74. PubMed ID: 19697241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of the octarepeat domain alters the misfolding pathway but not the folding pathway of the prion protein.
    Leliveld SR; Stitz L; Korth C
    Biochemistry; 2008 Jun; 47(23):6267-78. PubMed ID: 18473442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concealment of epitope by reduction and alkylation in prion protein.
    Yuan J; Kinter M; McGeehan J; Perry G; Kneale G; Gambetti P; Zou WQ
    Biochem Biophys Res Commun; 2005 Jan; 326(3):652-9. PubMed ID: 15596149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neurodegenerative conformational disease and its molecular bases].
    Li WW; Cai DF; Ren HM
    Sheng Li Ke Xue Jin Zhan; 2006 Apr; 37(2):97-102. PubMed ID: 16850610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chaperonin-mediated de novo generation of prion protein aggregates.
    Stöckel J; Hartl FU
    J Mol Biol; 2001 Nov; 313(4):861-72. PubMed ID: 11697909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation.
    Iwamaru Y; Shimizu Y; Imamura M; Murayama Y; Endo R; Tagawa Y; Ushiki-Kaku Y; Takenouchi T; Kitani H; Mohri S; Yokoyama T; Okada H
    J Neurochem; 2008 Nov; 107(3):636-46. PubMed ID: 18717818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.